How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

Size: px
Start display at page:

Download "How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949"

Transcription

1 ICH GCP Overview

2 What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are required to ensure and assess the safety, quality and efficacy of medicines.

3 How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 o Thalidomide- Declaration of Helsinki 1964

4 How did it evolve? o Belmont report n Conference center April 18 th 1979 n Ethical Principles and guidelines for the protection of human subjects of research)-tuskegee syphilis study n Created by the US Dept of Health, Education and Welfare (Health and Human Services)

5 History 1962 US FDA IND Guidelines 1964 Declaration of Helsinki 1968 Committee on Safety of Medicines, uk 1978 GCP, US FDA 1991 GCP, Europe 1996 ICH GCP 1997 ICH GCP Guideline

6 When did it begin? o I st conf. in 1990 in Brussels 3 regions participated o Representatives from

7 ICH parties o EU European Commission o o o o EFPIA European federation of pharmaceutical industries associations MHLW Ministry of health, Labor and welfare, Japan JPMA Japan Pharmaceuticals manufacturers Association US FDA o PhRMA Pharmaceutical Research & Manufacturers of America (1958) o WHO, TPP(Canada) o International federation of Pharmaceutical manufacturer s association

8 Key objective o To discuss and define the minimum standards for the development and registration of investigational products

9 The result? Many guidelines made o Most important- ICH GCP guidelines o Evolved in several steps o Consolidated guideline ICH E6 Sept 1997

10 ICH Guidelines: examples o Efficacy: clinical trials etc o Safety: pharmacovigilance, adverse drug reaction reporting, safety letters o Quality: raw materials, impurities, residual solvents etc o Multidisciplinary: common technical document, electronic submission, coding systems

11 The ICH Story Who: Why: How: Regulatory authorities and researchbased industry of the EU, US and Japan; WHO, Canada observers and EFTA (Iceland, Lichtenstein, Norway, Switzerland) Reduce unnecessary duplication and thereby contribute to the efficiency of drug development and registration for new pharmaceuticals Through the development of sciencebased, international guidelines and standards

12 What is GCP? A standard for the design, conduct, performance, monitoring,auditing, recording, analyses and reporting of clinical trials that provide assurance that the data and the reported results are credible, accurate and that the rights, integrity and confidentiality of trial subjects are protected. Main finding involved in monitoring and FDA audits.

13 Why is it needed? o To ensure the rights, safety and well being of the trial subjects are protected n Informed Consent n Belmont Report o Ensure the credibility of clinical trial data

14 The ICH GCP guideline o No acceptance of foreign clinical data o Regional variation in reg guidelines o Escalating costs o Extended time for registration o ICH region covers 85% of Pharm. sales

15 The ICH GCP guideline o Provide a unified standard for the EU, Japan and USA regions to facilitate mutual acceptance of clinical trial data by the regulatory authorities in these regions. o 8 sections

16 ICH GCP guideline 1. Glossary Common language for investigators/ sponsors/ethics committees Most if not all are on FDA-CFR

17 ICH GCP guideline 1. Glossary *AE: means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related *SAE: AE that in the view of either the investigator or sponsor, it results in any of the following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. **Blinded Study: A type of masking in which two or more parties involved with the clinical trial do not know which participants have been assigned which interventions. Typically, this includes the investigator and participant *21CFR312 ** Clinical Trials.gov

18 ICH GCP guideline 2.Principles of Good Clinical Practice 13 tenets of ICH GCP 3.Requirements for IRB/IEC Roles responsibilities and composition 4.Responsibilities of the investigator

19 ICH GCP guideline 5.Responsibilities of the sponsor 6.Requirements for clinical trial protocol and protocol amendments 7.Responsibility of the sponsor in the development of investigator s brochure. 8.Essential documents

20 Principles of ICH GCP q Ethical conduct as per Declaration of Helsinki GCP Regulatory Requirements q Risk- Benefit Primary concern- Subject

21 Principles of ICH GCP o Supportive data o Protocol Scientifically sound, clear, detailed o Ethical Clearance Study to be conducted in compliance to the protocol which has received EC approval

22 Principles of ICH GCP o Subject Care Medical decisions responsibility of qualified physician o Qualified staff By education, training, experience in their area of responsibility o Informed Consent

23 Principles of ICH GCP o Clinical Trial data Recorded, handled and stored to enable accurate reporting, interpretation and verification o Confidentiality

24 Principles of ICH GCP o Investigational Product Manufactured, handled and stored as per GMP q Used as per the protocol

25 Principles of ICH GCP o Quality Assurance Systems and procedures to ensure the Quality of every aspect of the trial

26 ICH Vs. non-ich o ICH: 17 countries o 15% world population o 82% drug production o 90% drug sales o 95% R&D o New Chemical Entities o Chronic & lifestyle diseases o Strong DRAs o $$$$$ o non-ich : 176 countries o 85% world population o 18% drug production o 10% drug sales o 5% R&D o Mainly generics o Life-threatening diseases o Weak DRAs (Drug regulatory affairs) o $

27 Issues in Developing Countries o The informed consent process o Economic Vulnerability o Patient doctor relationship o Education level

28 Role of GCP o Good clinical practice (gcp) is an international ethical & scientific standard for conducting clinical trials that involve the participation of human subjects o Compliance with this standard provides public assurance that the rights, safety & well-being of trial subjects are protected, which is consistent with the principles outlined in the declaration of helsinki o GCP also ensures the credibility of clinical trial data.

29 INTERNATIONAL ETHICAL STANDARDS o Professional standards for the protection of human subjects in research did not exist till late 1940 s. o Nuremberg tribunal held in 1945 and 1946 that voluntary consent of the human subject is absolutely essential o The Declaration of Helsinki outlines 12 principles by which physicians must conduct research in therapeutic & nontherapeutic interventions.

30 Fundamental Ethical Principles Guiding Protection of Human Subjects In Biomedical Research o RESPECT FOR PERSONS: Acknowledges the dignity & autonomy of individuals. This principle requires that subjects give their informed consent prior to participating in research. o BENEFICENCE: Obligates researchers to treat subjects fairly. o JUSTICE: requires the equitable selection of subjects in light of research setting & research purposes.

31 Principles Behind GCP o Before initiating any clinical trial, ANTICIPATED RISKS should be weighed against EXPECTED BENEFITS for the trial subject & society The RIGHTS, SAFETY & WELL BEING of trial subjects are the most important considerations & should prevail over the interests of science & society. The entire study procedure should be scientifically sound & detailed in a trial protocol. This protocol should receive a prior APPROVAL FROM AN IRB (Institutional Review Board)

32 ETHICAL REVIEW SHOULD DEFINE JUSTIFIABLE BOUNDARIES BETWEEN THE RIGHTS OF THE SUBJECT AND THE BENEFITS THAT MIGHT ACCRUE TO SOCIETY THROUGH SCIENTIFIC INFORMATION DEVELOPED IN CLINICAL TRIALS. Regulations have been established internationally, to ensure ethical & scientific conduct of trials

33 GOALS OF INTERNATIONAL HARMONIZATION OF REGULATORY REQUIREMENTS o SAFEGUARD PUBLIC HEALTH o ASSURE CONSUMER PROTECTION STANDARDS o FACILITATE AVAILABILITY OF SAFE AND EFFECTIVE PRODUCTS o ELIMINATE INCONSISTENT STANDARDS INTERNATIONALLY o FACILITATE MUTUAL ACCEPTANCE OF DATA FROM CLINICAL TRIALS

34 STAKEHOLDERS & THEIR RELATIONSHIPS SPONSOR INVESTIGATOR IRB SUBJECT REGULATORY AUTHORITY

35 Role of IRB s o Play a vital role in protecting human subjects in clinical trials. o They review trial protocols to ensure that. n informed consents are obtained from the subjects n subjects are not exposed to unreasonable risks o Establishment of EC s has become a cornerstone of protection of human subjects in clinical research

36 Protection of Human Subjects The investigator must request IRB approval for: n Protocol n Informed Consent Form/Advertisements/Other Information n Protocol amendment and /or Informed Consent Amendments n All sites at which patient activity will occur

37 Protection of Human Subjects o The investigator must request IRB approval for any change in the research activity o The investigator must submit progress reports to the IRB as required o The subject must be informed of any new information which might affect their decision to continue participation in the trial

38 Responsibilities of the Investigator q Conduct the research in accordance with the protocol and Good Clinical Practice (GCP) q Protect the rights, safety, and welfare of the subjects q Report all adverse events (serious and non-serious) q Retain study documents and medical records q Control the distribution and use of the study medication

39 Responsibilities of the Sponsor o The sponsor is responsible for implementing and maintaining quality assurance of data generated in compliance with the protocol o Sponsor is responsible for securing agreement from all involved parties to ensure direct access to all sites, source data & reports for the purpose of monitoring & auditing by regulatory authorities o Agreements made by the sponsor with the investigator should be in writing

40 Medical Care of Trial Subjects o During and following a subject s participation in a trial, the investigator & institution should ensure that adequate medical care is provided to deal with adverse events related to the trial o The investigator should inform the subject s primary physician about the trial & the subject s participation

41 Protection of Human Subjects o Must be signed and dated by the subject prior to study start o Language understandable to the subject o Subject Information Sheet approved by the Ethics Committee o The Consent Form must contain the elements required by GCP o Subject must be given a copy

42 Study Documentation n n n IRB approval letter Members of IRB and their qualifications/ affiliation Normal ranges of clinical laboratory

43 Study Documentation The investigator must keep: n Source documents p Medical records (including access to computer records) p Laboratory reports p ECGs, X-rays, etc. p Any other medical records, reports or notes (hospital admissions and discharges) n A subject identification list n Copies of all study related documentation

44 Medical Records o Sufficient information to support subject eligibility o This should be well documented (signed and dated) o Subject s participation in the study o Dates of visits o Procedures, investigations done o Observations, diagnoses o Medications taken (including study medication) o Adverse events / SAE s o Completion or withdrawal (reason) from the study o Source documents

45 Study Documentation The sponsor needs from the investigator: n Final drug accountability records n All used and unused supplies and medication n All required documents completed n Destruction or return of IP is also part of source docs

46 INVESTIGATIONAL PRODUCT o The trial subjects should be explained the correct use of the investigational product and compliance to these instructions should be checked periodically o Investigator should maintain records of the delivery of the product, the inventory, use by each subject as per protocol

47 Monitoring n The rights & well-being of human subjects are protected n The reported data are accurate, complete & verifiable from source documents n The conduct of the trial is in compliance with approved protocol & with applicable regulatory requirements

48 Questions?

49 Thank you!

Research Professionals Network Workshop Series

Research Professionals Network Workshop Series Research Professionals Network Workshop Series SO YOU THINK YOU KNOW GCP? Mary-Tara Roth Director, CRRO mtroth@bu.edu Gina Daniels Human Research Quality Manager gdaniels@bu.edu What is [ICH] GCP? an

More information

Good Clinical Practice

Good Clinical Practice Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie

More information

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of

More information

Ethical Issues in Clinical Trial & Development of Regulation Policy on Clinical Research

Ethical Issues in Clinical Trial & Development of Regulation Policy on Clinical Research Ethical Issues in Clinical Trial & Development of Regulation Policy on Clinical Research Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Department

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:

More information

Research Ethics and Good Clinical Practice. Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London

Research Ethics and Good Clinical Practice. Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London Research Ethics and Good Clinical Practice Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London History of Research Ethics Nuremberg Code End of WWII Nazi

More information

Conducted Under an IND to Support a

Conducted Under an IND to Support a Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.

More information

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by: GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training

More information

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies OFFICE FOR RESEACH PROCEDURE Sponsor Responsibilities in Investigator Initiated Studies 1. Purpose: To define Sponsor Responsibilities in the conduct of Investigator driven studies. 2. Scope: All phases

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National

More information

GCP Convergence Improves Transportability of Medical Device Clinical Data

GCP Convergence Improves Transportability of Medical Device Clinical Data GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled

More information

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

GCP/Clinical Investigation in Japan

GCP/Clinical Investigation in Japan GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)

More information

Clinical Research: A Multifaceted Discipline

Clinical Research: A Multifaceted Discipline Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri

More information

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE www.gratanet.com Among other regulations aimed at the implementation of the Agreement

More information

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010 IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized

More information

Institutional Review Board. Ensuring that the rights and welfare of participants in research are protected.

Institutional Review Board. Ensuring that the rights and welfare of participants in research are protected. Institutional Review Board Ensuring that the rights and welfare of participants in research are protected. Michael Linke, PhD, CIP Presenters Health Science Officer, Veterans Affairs Medical Center Associate

More information

ICH/GCP Guidelines Self-Evaluation Questionnaire

ICH/GCP Guidelines Self-Evaluation Questionnaire THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may

More information

INSTITUTIONAL ETHICS REVIEW COMMITTEE GLOSSARY

INSTITUTIONAL ETHICS REVIEW COMMITTEE GLOSSARY INSTITUTIONAL ETHICS REVIEW COMMITTEE Adverse events Amendment to the protocol Approval Assent Center for Clinical Trials Clinical research Clinical trials - Any untoward or unfavorable medical occurrence

More information

Overview of Privacy Requirements and Compliance Issues in International Clinical Trials

Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Health Care Compliance Association Research Compliance Conference October 18-20, 2009 Minneapolis, MN 1 Today s Presenters

More information

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles

More information

Adverse Event Reporting: During the Study

Adverse Event Reporting: During the Study Vol. 5, No. 8, August 2009 Can You Handle the Truth? Adverse Event Reporting: During the Study By S. Eric Ceh The reporting of adverse events (AEs) is a standard task for investigative sites involved in

More information

Institutional Review Board

Institutional Review Board Institutional Review Board Overview & Minimal Risk Research Jon Mark Hirshon, MD, MPH Vice-Chairman University of Maryland Institutional Review Board May 18, 2006 Jon Mark Hirshon, MD, MPH 1 Presentation

More information

Ethical Principles in Clinical Research. Disclaimer. Christine Grady Department of Bioethics NIH Clinical Center

Ethical Principles in Clinical Research. Disclaimer. Christine Grady Department of Bioethics NIH Clinical Center Ethical Principles in Clinical Research Christine Grady Department of Bioethics NIH Clinical Center Disclaimer The views expressed are mine and do not necessarily represent the positions or policies of

More information

Functional Classification of Medicine

Functional Classification of Medicine Research on Humans Functional Classification of Medicine Medicine and medical intervention can take any of five forms: (1) Therapeutic (curative): seeks to cure a disease or ailment. (2) Palliative: seeks

More information

Clinical trials from CRA s point of view

Clinical trials from CRA s point of view Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical

More information

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014 Annual Research Administrators Symposium IRB Compliance Thursday, July 31, 2014 Why IRB Compliance Is Required for Grant Submissions Topics to Cover Today What is an IRB? Why IRB review is required? Regulatory

More information

University joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015

University joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015 University joins Industry: Clinical Trials & Drug Safety Aula Magna-Facultad de Farmacia 11 Marzo 2015 Contents Background, key points and basic knowledge Department tasks and responsibilities Importance

More information

Ethical Principles in Clinical Research

Ethical Principles in Clinical Research Ethical Principles in Clinical Research Christine Grady NIH Clinical Center Department of Bioethics No conflicts of interest. Views presented are mine and do not necessarily represent positions or policies

More information

Implementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.

Implementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G. Implementation of the EU-law Tom Van Paepegem Quality co-ordinator D.R.U.G. History (1) World War II: Experiments by Nazi-doctors 1946: Nüremberg process 1947: Nüremberg codeddd History (2) 10 basic ethical

More information

Regulatory and ethical requirements in medical devices studies. France

Regulatory and ethical requirements in medical devices studies. France Regulatory and ethical in medical devices studies France SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within

More information

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

SERIOUS ADVERSE EVENTS

SERIOUS ADVERSE EVENTS EVENTS Introduction Timely reporting of Serious Adverse Events (SAEs) is required by regulations of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Such reporting is not

More information

S A I N T M A RY S E M I N A RY O C T O B E R 1 9,

S A I N T M A RY S E M I N A RY O C T O B E R 1 9, IRB BASICS FOR ADMINISTRATORS S A I N T M A RY S E M I N A RY O C T O B E R 1 9, 2 0 1 6 JOHN CARROLL UNIVERSITY Catherine Anson, MA, CRA, CIM Director of Sponsored Research Assistant IRB Chair Carole

More information

WCG ACADEMY COURSE OVERVIEW

WCG ACADEMY COURSE OVERVIEW WCG ACADEMY COURSE OVERVIEW Investigator Course Title Documentation of Informed Consent Duration Ethical Principles Underlying Consent Documentation Long Form Short Form Consent Records Special Considerations

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

Regulatory and ethical requirements in medical devices studies. Turkey

Regulatory and ethical requirements in medical devices studies. Turkey Regulatory and ethical in medical devices studies Turkey SECTIONS A.Type of research H. Data Protection SECTIONS A.Type of research H. Data Protection We have differentiated 8 types of research: Medical

More information

Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski

Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Agenda Why are clinical trials conducted? History Guidelines and Regulations When are trials conducted? Requirements

More information

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA Good Clinical Practice, GCP Clinical Trials 101 GCIG CCRN QA Monica Bacon/Adriana Chavez-Blanco GCIG-CCRN Background: 1949 The Nuremburg Code 1964 Declaration of Helsinki (World Medical Association) 1990

More information

Good Clinical Practice Compliance

Good Clinical Practice Compliance Good Clinical Practice Compliance Pharmaceutical Regulatory & Compliance Congress Greg Levine LLP Agenda? GCP compliance rules What is the law? What other (non-binding) standards apply? What are the unwritten

More information

SWOG

SWOG SWOG http://swog.org Page 1 of 5 pages Original Release Date: July 1985 Departments Affected: All Revision Date: April 2018 Introduction SERIOUS ADVERSE EVENTS The timely reporting of serious adverse events

More information

Regulatory Aspects of Pharmacovigilance

Regulatory Aspects of Pharmacovigilance Regulatory Aspects of Pharmacovigilance Deirdre Mc Carthy Pia Caduff-Janosa Training Course Uppsala 2012 Agenda Risk based approach to spontaneous reporting (incl clinical trials) -> Pia Caduff-Janosa

More information

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use

More information

Melbourne Health Guidelines Cover Sheet

Melbourne Health Guidelines Cover Sheet Melbourne Guidelines Cover Sheet NAME OF DEPARTMENT OFFICE FOR RESEARCH NAME OF DOCUMENT Clinical Trials Involving Therapeutic Products and Other Clinical Research NUMBER 18.8 ASSOCIATED MELBOURNE HEALTH

More information

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee) Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research

More information

Trends in Oversight of Human Research Protections?

Trends in Oversight of Human Research Protections? Trends in Oversight of Human Research Protections? Greg Koski, PhD, MD Associate Professor, Harvard Medical School Senior Scientist, James Mongan Institute for Health Policy Former Director, Office for

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training):

Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Principles of GCP, Investigator Responsibilities, Essential Documents v3 01-Feb-2017 Objectives To provide refresher training on ICH GCP

More information

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients

More information

Streamlining IRB Procedures for Expanded Access

Streamlining IRB Procedures for Expanded Access Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs

More information

HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP)

HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION WHO Library Cataloguing-in-Publication Data

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

Understanding Reporting Obligations to the IRB

Understanding Reporting Obligations to the IRB Understanding Reporting Obligations to the IRB fully accredited since 2006 May 13 & 15, 2014 Mitchell E. Parrish, JD, RAC, CIP Regulatory Attorney 2 3 WEBINAR HOUSEKEEPING Questions & Answers Feel free

More information

GOOD CLINICAL PRACTICE (GCP) Series Catalog

GOOD CLINICAL PRACTICE (GCP) Series Catalog GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational

More information

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA SAE Reporting Timelines, Causality Assessment And Compensation Pawandeep Kaur Associate Medical Director CDSA Objective Background Important definitions SAE Reporting Timelines Causality Assessment Compensation

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX)

University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX) University of the Virgin Islands Institutional Review Board (IRB) IRB Basics for Social Science Senior Seminar (STT/STX) Ethics and Human Subject Protections Presented by: Olusola Ewulo, M.S. Director,

More information

The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation

The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation The Role of the IRB in Clinical Trials: What Patients and Families Need to Know Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation 1 CAC2 Values v Put the children and their families first in

More information

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.

ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. 25 October 2017: University of Rochester Achieving High Quality Clinical Research

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

The Right Prescription for Working with Investigational Drug Service at BMC

The Right Prescription for Working with Investigational Drug Service at BMC The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational

More information

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

GUIDELINES FOR CONDUCTING CLINICAL TRIALS. GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,

More information

Guidance for Adverse Event Report from çachieving Guidance in Clinical Trial Safety Information among Stakeholderé Forum for Ethical Review Committee

Guidance for Adverse Event Report from çachieving Guidance in Clinical Trial Safety Information among Stakeholderé Forum for Ethical Review Committee Guidance for Adverse Event Report from çachieving Guidance in Clinical Trial Safety Information among Stakeholderé Forum for Ethical Review Committee in Thailand (FERCIT) June. 2011 Preface Practice in

More information

Human Subjects Protection: Training for Research Teams

Human Subjects Protection: Training for Research Teams Human Subjects Protection: Training for Research Teams Walter L. Calmbach MD MPH South Texas Ambulatory Research Network (STARNet) Dept. of Family & Community Medicine Univ. of Texas Health Science Center

More information

Implementing Good Clinical Practice at an Academic Research Institution

Implementing Good Clinical Practice at an Academic Research Institution Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of

More information

Effective Date: April 2014 Revision: September 29, 2017

Effective Date: April 2014 Revision: September 29, 2017 TITLE: Standard Operating Procedure (SOP) Statement of Authority and Purpose NUMBER: NSHA REB-SOP-1-001 Effective Date: April 2014 Revision: September 29, 2017 Applies To: All REB members and Office Personnel

More information

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition)

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition) 312.300 (c) Disposition of unused drug. The person who ships the drug under paragraph (a) of this section shall assure the return of all unused supplies of the drug from individual investigators whenever

More information

Practical Conduct of Clinical Trials

Practical Conduct of Clinical Trials Practical Conduct of Clinical Trials Overview Regulation of clinical trials SA as a clinical trial destination The clinical trial process Phases of clinical development Different study designs Clinical

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

Standard Operating Procedure

Standard Operating Procedure Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if

More information

Compliance and Quality Monitoring: What, Why, When, and How

Compliance and Quality Monitoring: What, Why, When, and How Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics

More information

Clinical trial applications in the EU and US

Clinical trial applications in the EU and US Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation

More information

SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP)

SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) Date of Implementation: 1 August 1998 Date of First Revision: 1 October 1999 Printed in July 1998, August 1998 and September 1999. Adapted from the

More information

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia "From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

Establishment of Clinical Trial Infrastructure

Establishment of Clinical Trial Infrastructure Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan

More information

11.0 FDA-Regulated Research

11.0 FDA-Regulated Research 11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the

More information

Amanda A. Hastings, MSHL Education Specialist USF Division of Research Integrity & Compliance

Amanda A. Hastings, MSHL Education Specialist USF Division of Research Integrity & Compliance Amanda A. Hastings, MSHL Education Specialist USF Division of Research Integrity & Compliance 813-974-5452 Research Ethics: Historical Events Syphilis Study in Tuskegee Begins Inoculation Studies in Guatemala

More information

ANNEX. CHAPTER I General principles

ANNEX. CHAPTER I General principles ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I

More information

GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018

GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore

More information

Safety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs)

Safety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Version 1.4 Effective date: 1 December 2011 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision

More information

Regulatory issues for academicled multinational trials in Asia: Who takes responsibility?

Regulatory issues for academicled multinational trials in Asia: Who takes responsibility? CVCT Asia Workshop, 15 July 2018 Regulatory issues for academicled multinational trials in Asia: Who takes responsibility? Commentary : Kaori Shinagawa, MD, PhD Senior Scientist for Clinical Medicine Pharmaceuticals

More information

PARTICIPANT RIGHTS AND PRIVACY. Tammy Stewart, CHRC & Jenny Bernhard, CHPC, CHC

PARTICIPANT RIGHTS AND PRIVACY. Tammy Stewart, CHRC & Jenny Bernhard, CHPC, CHC PARTICIPANT RIGHTS AND PRIVACY Tammy Stewart, CHRC & Jenny Bernhard, CHPC, CHC Presentation Outline By the end of this presentation, you will have an understanding of: The history which lead to current

More information

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Expedited Reporting Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Journal of Clinical Research Best Practices Vol. 7, No. 1, January 2011 Can You

More information

WMA Declaration of Helsinki Ethical Principles f or Medical Research Involving Human Subjects

WMA Declaration of Helsinki Ethical Principles f or Medical Research Involving Human Subjects WMA Declaration of Helsinki Ethical Principles f or Medical Research Involving Human Subjects Note: Modifications and insertions highlighted and compared to previous 2008 wording by Gillian Vale, Administrator,

More information

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR

More information